A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL

Trial Profile

A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2017 Status changed from discontinued to active, no longer recruiting.
    • 15 May 2017 Status changed from discontinued to active, no longer recruiting.
    • 10 May 2017 Status changed from suspended to discontinued, due to recruitment difficulties.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top